Safety Study of a Plant-based H5 Virus-Like Particles (VLP) Vaccine in Healthy Adults

NCT00984945 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Virus Diseases
RNA Virus Infections
Respiratory Tract Diseases
Respiratory Tract Infections

Interventions

BIOLOGICAL: H5 VLP pandemic influenza vaccine 5 µg
BIOLOGICAL: H5 VLP pandemic influenza vaccine 10 µg
BIOLOGICAL: H5 VLP pandemic influenza vaccine 20 µg
BIOLOGICAL: Placebo

Sponsor

Medicago